Recoiled Stocks in Momentum- Grifols, S.A. (NASDAQ:GRFS), Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Grifols, S.A. (NASDAQ:GRFS) [Trend Analysis] runs in leading trade, it moving up 4.87% to traded at $15.30. The firm has price volatility of 1.60% for a week and 1.73% for a month. Grifols (GRFS) decided to buy Nucleic Acid Testing donor screening unit from the U.S. Company Hologic for $1.85 billion.

This contract encompasses research, development and manufacture of assays and instruments activities using NAT technology that makes possible to detect the presence of infectious agents in blood and plasma donations, contributing to greater transfusion safety. The assets acquired comprise a production plant in San Diego as well as development rights, licenses to patents and access to product manufacturers.

Victor GrífolsSr, Chairman and CEO of Grifols said, “This acquisition is part of the growth strategy foreseen for the Diagnostic Division. It is an obvious step that allows us to strengthen a leading position that we first achieved in 2014 in transfusion diagnostics with the acquisition of assets from Novartis, which, among other things, included the rights to market transfusion medicine assays and instruments using NAT technology.”

Narrow down four to firm performance, its weekly performance was 0.21% and monthly performance was -6.24%. The stock price of GRFS is moving up from its 20 days moving average with 1.75% and isolated positively from 50 days moving average with 1.87%.

Several matter pinch shares of Valeant Pharmaceuticals International,  (NYSE:VRX) [Trend Analysis], as shares plunging -5.20% to $13.39 with a share volume of 4.21 Million. Troubled Valeant Pharmaceuticals International (VRX) declared that departure of three executives, as the business continues to restructure at the close of a punishing 2016.

The Canadian company has already lost more than 80% of its market value since the year began, amid debt woes, the Philidor scandal, and a criminal investigation by the US Securities and Exchange Commission into its accounting and pricing practices. The stock is going forward its 52-week low with -2.91% and moving down from its 52-week high price with -88.85%. To have technical analysis views, liquidity ratio of a company was calculated 1.50 as evaluated with its debt to equity ratio of 7.31. The float short ratio was 9.82%, as compared to sentiment indicator; Short Ratio was 1.83.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *